Michael Derks

441 total citations
24 papers, 307 citations indexed

About

Michael Derks is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Michael Derks has authored 24 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Michael Derks's work include Drug Transport and Resistance Mechanisms (8 papers), Lipoproteins and Cardiovascular Health (5 papers) and Neuroendocrine regulation and behavior (4 papers). Michael Derks is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Lipoproteins and Cardiovascular Health (5 papers) and Neuroendocrine regulation and behavior (4 papers). Michael Derks collaborates with scholars based in Switzerland, United Kingdom and United States. Michael Derks's co-authors include Mary C. Phelan, Markus Abt, Stephen Fowler, Olaf Kuhlmann, Georgina Meneses‐Lorente, Christoph Wandel, Lisa Squassante, Marta del Valle Rubido, Federico Bolognani and Omar Khwaja and has published in prestigious journals such as Scientific Reports, Science Translational Medicine and Atherosclerosis.

In The Last Decade

Michael Derks

23 papers receiving 296 citations

Peers

Michael Derks
Rebekka Pohl Germany
Verónica González Spain
Xiaodan Liu China
Xiaohua Liu China
Kerstin Albus Germany
Daniel Kofink Netherlands
Bethany Dubois United States
Jose Martinez Spain
Min‐Tzu Lo United States
Rebekka Pohl Germany
Michael Derks
Citations per year, relative to Michael Derks Michael Derks (= 1×) peers Rebekka Pohl

Countries citing papers authored by Michael Derks

Since Specialization
Citations

This map shows the geographic impact of Michael Derks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Derks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Derks more than expected).

Fields of papers citing papers by Michael Derks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Derks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Derks. The network helps show where Michael Derks may publish in the future.

Co-authorship network of co-authors of Michael Derks

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Derks. A scholar is included among the top collaborators of Michael Derks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Derks. Michael Derks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Derks, Michael, et al.. (2024). A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations. Journal of Pharmacokinetics and Pharmacodynamics. 51(3). 227–242.
2.
Hipp, Joerg F., Frédéric Knoflach, Robert A. Comley, et al.. (2021). Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Scientific Reports. 11(1). 7700–7700. 24 indexed citations
3.
Derks, Michael, Andreas Guenther, Lisa Squassante, et al.. (2021). Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. Expert Opinion on Investigational Drugs. 30(8). 893–901. 5 indexed citations
4.
Bentley, Darren, et al.. (2020). PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration. Journal of Pharmacokinetics and Pharmacodynamics. 47(5). 447–459. 1 indexed citations
5.
Derks, Michael, et al.. (2020). Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. Advances in Therapy. 37(11). 4720–4729. 4 indexed citations
6.
7.
Bolognani, Federico, Marta del Valle Rubido, Lisa Squassante, et al.. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine. 11(491). 75 indexed citations
8.
Delporte, Marie‐Laure, Scott Schobel, Lothar Lindemann, et al.. (2017). Results and evaluation of a first‐in‐human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods. British Journal of Clinical Pharmacology. 84(3). 445–455. 7 indexed citations
9.
Nieforth, Keith, Hisham Abdallah, Patrick F. Smith, et al.. (2013). Clinical Pharmacology Knowledge, Opportunities and Working Strengths (CPKNOWS): a competency model for pursuit of excellence in clinical pharmacology. British Journal of Clinical Pharmacology. 76(6). 841–845. 2 indexed citations
10.
Young, Annie, Judith Anzures‐Cabrera, & Michael Derks. (2012). No clinically relevant drug–drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30). International Journal of Clinical Pharmacology and Therapeutics. 50(4). 248–256. 4 indexed citations
11.
Derks, Michael, et al.. (2011). Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation. 31(5). 325–335. 17 indexed citations
12.
13.
Niesor, Eric J., Evelyne Chaput, Andreas Staempfli, Michael Derks, & David Kallend. (2011). 198 EFFECT OF DALCETRAPIB ON NON-CHOLESTEROL MARKERS OF CHOLESTEROL HOMEOSTASIS IN HEALTHY SUBJECTS. Atherosclerosis Supplements. 12(1). 44–44. 2 indexed citations
14.
Niesor, Eric J., Evelyne Chaput, Andreas Staempfli, et al.. (2011). Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 219(2). 761–767. 17 indexed citations
15.
Derks, Michael, et al.. (2010). Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. European Journal of Clinical Pharmacology. 66(8). 775–783. 14 indexed citations
16.
Derks, Michael, Markus Abt, & Mary C. Phelan. (2010). Lack of clinically relevant drug–drug interactions when dalcetrapib is co‐administered with ezetimibe. British Journal of Clinical Pharmacology. 70(6). 825–833. 12 indexed citations
17.
Derks, Michael, et al.. (2010). Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug‐Drug Interactions. The Journal of Clinical Pharmacology. 50(10). 1188–1201. 22 indexed citations
18.
Derks, Michael, et al.. (2010). No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs. 19(10). 1135–1145. 18 indexed citations
19.
Derks, Michael, Stephen Fowler, & Olaf Kuhlmann. (2009). A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clinical Therapeutics. 31(3). 586–599. 24 indexed citations
20.
Biniek, R., M. Schulz, H. Lehmann, et al.. (1988). Intrathecal production of HIV antibodies in suspected AIDS encephalopathy. Journal of Neurology. 235(3). 131–135. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebekka Pohl Breakdown of academic impact, for papers by Verónica González Breakdown of academic impact, for papers by Xiaodan Liu Breakdown of academic impact, for papers by Xiaohua Liu Breakdown of academic impact, for papers by Kerstin Albus Breakdown of academic impact, for papers by Daniel Kofink Breakdown of academic impact, for papers by Bethany Dubois Breakdown of academic impact, for papers by Jose Martinez Breakdown of academic impact, for papers by Min‐Tzu Lo
Rankless by CCL
2026